secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lite Strategy, Inc. (LITS)
CIK:        0001262104
Form:       8-K
Filed at:   2023-09-26T23:59:59+00:00
Accession:  0001193125-23-242526
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MEI Pharma FY2023 net loss $31.8M; cash $100.7M; merger fails, CEO changed
--------------------------------------------------------------------------

- Net loss $31.8M ($4.78/share) vs $54.5M ($8.75/share) prior year; revenue $48.8M, up from $40.7M.
- Cash and equivalents $100.7M, no debt; cash used in operations $52.5M.
- Stockholders rejected Infinity Pharmaceuticals merger (47.86% for, 51.44% against); agreement terminated.
- David M. Urso appointed CEO (June 2023); Jay File appointed CFO (effective Aug 2023).
- Voruciclib+venetoclax data early 2024; ME-344+bevacizumab data H1 2024; workforce reduced 61% to 41 employees.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1262104/000119312523242526/0001193125-23-242526-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1262104/000119312523242526/d548878d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-242526

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer